VRX stock


Valeant Pharmaceuticals Intl Inc (VRX) Draws a Price Target Lift from Neil Maruoka Ahead of 4Q Earnings

Canaccord’s Neil Maruoka jumps up his price target on VRX, but even with more optimism, still angles for 5% downside potential from the stock.

Valeant Pharmaceuticals Intl Inc (VRX) Subsidiary Salix Receives Notification of PDUFA Date Extension

Salix Pharmaceuticals, a wholly owned subsidiary of Valeant Pharmaceuticals Intl Inc (NYSE:VRX), announced today that the U.S. …

Bearish Valeant Pharmaceuticals Intl Inc (VRX) Analyst Sent Shares Tumbling

Goldman Sachs’ Dana Flanders sheds new insights on Valeant from a bearish standpoint, spotting 5% in loss potential for the stock.

Don’t Get Jittery on Valeant Pharmaceuticals Intl Inc Just Because of Prospective Cosmo Rivalry, Argues Louise Chen

Cantor’s Louise Chen dismisses Valeant share weakness today, making a bullish case that the majority of Xifaxan’s sales stem from IBS-D; not Traveler’s Diarrhea.

Valeant Pharmaceuticals Intl Inc (VRX) Spurs Sidelined Analyst to Boost Price Target

H.C. Wainwright’s Ram Selvaraju now bets on 4% upside potential for Valeant shares.

Valeant Pharmaceuticals Intl Inc (VRX) Is Taking Reassuring Strides on Back of Strong International Segment

BTIG’s Tim Chiang notes that with various positives soaring in Valeant’s favor, these are mostly reflected in the stock’s recently climbing levels.

Valeant Pharmaceuticals Intl Inc’s (VRX) Bausch + Lomb Scores CE Mark for Ophthalmic Surgical Platform

Valeant Pharmaceuticals Intl Inc (NYSE:VRX) announced this morning that its subsidiary Bausch + Lomb has received …

Louise Chen Roots for Valeant Pharmaceuticals Intl Inc (VRX) in the New Year on Back of Ocular Redness Asset’s FDA Nod

Cantor’s Louise Chen believes Valeant will surpass $8 billion in sales in 2018, and says the set-up for the rebounding giant “keeps getting better” following Lumify’s approval.